EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access

Delafloxacin: what does a new fluoroquinolone offer?

Emilia Cercenado iD, Oscar Murillo iD

Revista Española de Quimioterapia · 27.03.2026 · 39 (2) · 104

DOI: 10.37201/req/151.2026 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Revista Española de Quimioterapia, online erschienen am 11.03.2026. Verfasst von Emilia Cercenado und 1 weiteren Autor:innen. Beteiligte Einrichtung: Servicio de Microbiología Clínica y Enfermedades Infecciosas, Hospital General Universitario Gregorio Marañón, Madrid, Spain. ecercenado@gmail.com. Hauptthemen laut MEDLINE: Fluoroquinolones, Anti-Bacterial Agents. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Delafloxacin is a novel anionic fluoroquinolone with a different chemical structure from currently marketed fluoroquinolones, which gives it distinct physicochemical characteristics, being active in both acidic and neutral environments. Delafloxacin is also unique in showing a dual-targeted equipotent inhibition of the essential bacterial enzymes DNA gyrase and topoisomerase IV, which may explain the very low frequencies of spontaneous mutations in vitro. It shows potent in vitro activity against a broad spectrum of Gram-negative bacteria, including some fluoroquinolone-resistant strains, and increased efficiency against Gram-positive bacteria, including methicillin-resistant Staphylococcus aureus, although it is always necessary to determine the in vitro activity of delafloxacin against fluoroquinolone-resistant isolates. Delafloxacin exhibits linear pharmacokinetics, a wide volume of distribution, and a concentration-dependent pattern of antimicrobial killing, a property that allows the use of high doses for greater effectiveness in some difficult-to-treat infections. Delafloxacin is available for clinical use in oral and intravenous formulations and has been approved for the treatment of acute bacterial skin and skin-structure infections and community-acquired bacterial pneumonia based on the results from phase II and III clinical trials. Overall, delafloxacin has been well tolerated and has a low profile of drug-drug interactions. Its activity in local acidic environments and biofilms could play a role in the treatment of biofilm-related infections such as osteoarticular and medical device-associated infections, and due to its broad spectrum, it can also be useful in polymicrobial infections. Delafloxacin is an interesting new addition to the therapeutic arsenal against common and difficult-to-treat infections.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

FluoroquinolonesAnti-Bacterial AgentsHumansGram-Negative BacteriaMicrobial Sensitivity TestsDrug Resistance, BacterialDNA Topoisomerase IV

Stichwörter der Autor:innen

Acute bacterial skin and skin structure infectionsCommunity-acquired bacterial pneumoniaDelafloxacinFluoroquinolonesMethicillin-resistant Staphylococcus aureusResistanceTopoisomerases

Substanzen

FluoroquinolonesdelafloxacinAnti-Bacterial AgentsDNA Topoisomerase IV

Autor:innen und Institutionen

  • Servicio de Microbiología Clínica y Enfermedades Infecciosas, Hospital General Universitario Gregorio Marañón, Madrid, Spain. ecercenado@gmail.com.
  • Servicio de Enfermedades Infecciosas, Hospital Universitari Bellvitge, L'Hospitalet de Llobregat, Spain.
  • CIBER de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III, Madrid, España.

ORCID-Profile: Emilia Cercenado, Oscar Murillo

Zitieren

APA

Cercenado, E., & Murillo, O. (2026). Delafloxacin: what does a new fluoroquinolone offer?. Revista Española de Quimioterapia, 39(2), 104. https://doi.org/10.37201/req/151.2026

Vancouver

Cercenado E, Murillo O. Delafloxacin: what does a new fluoroquinolone offer?. Revista Española de Quimioterapia. 2026;39(2):104. doi:10.37201/req/151.2026

BibTeX
@article{Cercenado2026,
  author = {Cercenado, Emilia and Murillo, Oscar},
  title = {Delafloxacin: what does a new fluoroquinolone offer?},
  journal = {Revista Española de Quimioterapia},
  year = {2026},
  volume = {39},
  number = {2},
  pages = {104},
  doi = {10.37201/req/151.2026}
}
Kostenlos starten →